Amgen Roars to Life with Q2 Beat, Raises Guidance on Strong Growth Drivers

Amgen reported strong Q2 2026 results, exceeding analyst estimates and pushing its full-year guidance up.

The biotech giant's adjusted earnings reached $6.29 per share on revenue of $10.05 billion, beating expectations with growth in key franchises like Repatha and Evenity.

Chief Executive Officer Robert Bradway said the company's six key growth drivers grew 26% year over year and now account for nearly 70% of product sales.

The company raised its full-year revenue projection to $38.2 billion to $39.4 billion, with adjusted EPS expected between $22.30 and $23.50.